semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-85.0,  Pulmonary Disease, Chronic Obstructive Subjects eligible for enrolment in this study must meet all of the following Male or female of at least 40 years of age at screening. To be eligible for entry into the study, females of childbearing potential must commit to the consistent and correct use of an acceptable method of birth control starting on the day of visit 1, throughout the clinical trial, and for a period after the trial to account for elimination of the drug (minimum of six days), as defined by any one of the following Abstinence Females of childbearing potential who are not sexually active must commit to complete abstinence from intercourse Oral contraceptive (either combined estrogen/progestin or progestin only) Injectable progestogen Implants of levonorgestrel or etonogestrel Percutaneous contraceptive patches Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year Male partner who is sterile (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study and is the sole sexual partner for that female subject, or Double-barrier method; condom or occlusive cap (diaphragm or cervical /vault caps) plus spermicide  Subjects meeting any of the following must not be enrolled in the study Diagnosis of pneumonia, congestive heart failure (CHF), or other complicating co-morbid condition while hospitalized within the last 6 months for an exacerbation of COPD Historical or current evidence of clinically significant uncontrolled disease including, but not limited to, those listed below. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subjects at risk through study participation, or which would affect the safety analysis or other analyses if the disease/condition exacerbated during the study A previous lung resection surgery (e.g. lobectomy, pneumonectomy, etc) within the year preceding Visit 1 (Screening) Asthma as primary diagnosis Lung cancer Cystic fibrosis, pulmonary fibrosis, active tuberculosis, or sarcoidosis Clinically significant cardiac arrhythmias Uncontrolled hypertension Unstable angina
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Non-Small Cell Lung Cancer complete resection by lobectomy, bi-lobectomy or pneumonectomy of NSCLC pN1 or pN2 disease signed informed consent for participation in the study Karnofsky Performance Status (KPS) higher than 70%  presence of distant metastases N2 diagnosed before surgery in imaging and/or mediastinoscopy previous radiotherapy to the chest no or inadequate mediastinal nodal dissection  FEV1 after surgery lower than 1.0 liter any active infectious process (including fistula formation) in the chest
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  ST Elevation (STEMI) Myocardial Infarction of Other Sites *Selection Any patient hospitalised in the CCU of the participating centers with a diagnosis of a first MI with ST segment elevation and/or Q wave at admission with troponin elevation seen within the first 24 hours after symptom onset aged between 18 and 80 years is selected consent emergency clause: His/her informed consent is obtained and he/she signs the consent form or However, if a member of the patients' family is present, his/her consent must be obtained or no consent *Inclusion The first transthoracic echocardiography is performed at day 4±2 in all patients selected In the presence of at least 3 akinetic LV segments at the transthoracic echocardiography, the patient is included  *Non-selection Informed consent not obtained Patients with diagnosis of previous MI, hypertrophic or dilated cardiomyopathy, significant valvular heart disease, chronic atrial fibrillation, or pace maker or any permanently implanted device susceptible to interfere with LV remodelling Patients with preexisting heart failure Patients having undergone previous cardiac surgery Patients having received chemotherapy susceptible to induce LV remodeling (anthracyclines) Patients with an associated short-time life-threatening disease Patients with poor echogenicity Patients without health insurance
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  COPD Exacerbation years old or over have known or suspected COPD based on pulmonary function test, arterial blood gas, clinical history, physical examination, and chest radiograph worsening of dyspnea within 2 weeks partial pressure of arterial carbon dioxide (PaCO2) >45 mmHg respiratory rate >24/min arterial pH <7.35 partial pressure of arterial oxygen (PaO2) <50 mmHg under room air  hypersensitivity to anticholinergics and to magnesium sulfate patients that received anticholinergics within 6 hours before ED admission systolic arterial pressure <90 mmHg or need to vasoactive drugs
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COPD CT Bronchodilation age 40 or more Smoking history > 10 pack-years post bronchodilator FEV1/VC < 0.7  COPD exacerbation or infection in the 4 weeks before the study Concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer) pulmonary resection active malignancy or malignancy of any organ system within the past 5 years
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Chronic Obstructive Pulmonary Disease Male or female subject, age > 40 years, current or ex-smokers Planned lung resection for primary lung cancer of any size Patients with COPD: irreversible airflow limitation (postbronchodilator FEV1/FVC < 70% according to GOLD guidelines). Patients already receiving inhalative therapy can continue their medication. Patients showing a partial reversibility after bronchodilation (postbronchodilator FEV1 increase > 150 ml but < 200ml) and complaining respiratory symptoms (e.g. dyspnea at exertion) will be treated preoperatively with a short-acting beta-agonist to achieve optimal perioperative conditions Patients without COPD: postbronchodilator FEV1/FVC > 70% Patients have to be in clinical stable condition (no symptoms of respiratory tract infection for at least 2 weeks prior to the study) Written informed consent  Patients with a history of asthma or other active lung disease Lung resection for other reasons than lung cancer (e.g. infective diseases like bronchiectasis)
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Malignant Skin Melanoma T0 Stage III Melanoma Stage IV Melanoma Amplification Patients with histologically proven melanoma with either c-KIT mutation or C-KIT amplification (without BRAF or NRAS mutation) Unresectable primary or stage III or stage IV melanoma Measurable disease (RECIST) The of patients with primary tumor or metastasis accessible to sequential biopsies will be favored. If such lesions are present, biopsies are mandatory and not optional No more than 1 previous specific therapy excluding tyrosine kinase inhibitors. 4 weeks wash out will be needed after cytotoxic therapy , 12 weeks wash out after anti -CTLA4 therapy or any immunological treatment No radiotherapy within 4 weeks ; previously irradiated lesion will not be considered as measurable unless progression at ECOG performance status < 2 WBC ≥ 3,000/mm³ PNN ≥ 1,500/mm³ (G-CSF allowed) platelets ≥ 100,000/mm³  Patients refusal Age < 18 years Fertile women who do not want or cannot use effective contraception during the study and up to 8 weeks after the end of study Women pregnant or nursing Women with positive pregnancy test at or before treatment initiation Fertile and sexually active men whose partner are fertile women who do not use effective contraception Clinical and/or radiographic evidence of active cerebral metastases Severe evolutive infection Known HIV infection Concomitant therapy with any other anti-cancer, immunomodulator or immunosuppressing agent or radiotherapy (except palliative care if bone metastases, after acceptance of principal investigator)
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Vitamin D Deficiency in Older Persons Long term indication for living in a residential home for the elderly Age > 65 years Vitamin D deficiency (serum 25 hydroxycholecholecalciferol (25(OH)D3 < 50 nmol/l) Informed Consent  Hypercalcemia (serum CA > 2.60 mmol/l) Life expectancy < 1/2 year Multivitamin use including > 400 IE vit D Non-functional dominant arm
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Pulmonary Disease, Chronic Obstructive Asthma Healthy volunteers Males and females aged 18-65 years Body Mass Index (BMI) between 18.0 and 28.0 kg/m2 Non or ex-smokers who smoked < 5 pack years and stopped smoking > 1 year Normal blood pressure and heart rate Normal electrocardiogram (ECG,12 lead) Normal laboratory tests; Patients with Asthma Males and females aged 21-65 years BMI between 18.0 and 28.0 kg/m2  All subjects Blood donation or blood loss in the previous 8 weeks Positive HIV1 or HIV2 serology Positive acute or chronic Hepatitis B or Hepatitis C Unsuitable veins for repeated venipuncture Female patients: pregnant, positive pregnancy test, lactating mother or lack of efficient contraception History of substance abuse or positive urine drug screen Abnormal laboratory values suggesting an unknown disease and requiring further clinical investigation Uncontrolled cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric clinically significant disorder Participation in another clinical trial in the previous 8 weeks; participation in study using radioactive material within 1 calendar year
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 30.0-80.0,  COPD Male or female subjects between and including the ages of 30 and 80 years. Females of childbearing potential may be included provided they are not pregnant or are not nursing. 2. Subjects with a diagnosis of moderate to very severe chronic obstructive pulmonary disease as defined by the Global Initiative for COPD (GOLD, 2008 update) and who meet the following for stage ll IV disease: a) Subjects must have a post-bronchodilator FEV1/FEV ratio <70% and FEV1 of <80% of the predicted value for age, height, and sex using the III standards (Hankinson, 1999). 3. Subjects must have a smoking history of at least 10 pack-years. 4. Subjects must have stable disease for at least 1 month prior to enrollment with no changes in the maintenance treatment for COPD in this period. -  History of an exacerbation or other significant disease instability during the month preceding enrollment. 2. A primary diagnosis of asthma or bronchiectasis. 3. Inability to vibrate the reed of the Lung Flute® consistently because of severely expiratory flow rate. 4. Subject with any evidence of significant concomitant clinical disease that, in the opinion of the investigator, could interfere with the conduct of the study or safety of the subject. 5. Pregnant or nursing females or females intending to become pregnant during the course of the study. 6. Use of any investigational drug within one month or 6 half-lives (which-ever is greater) of the enrollment visit. 7. Inability to comprehend or willingness to follow the study requirements including attendance at out-patient clinic visit and participation in testing as called for by the protocol. 8. Patients currently using the Lung Flute. -
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Chronic Obstructive Pulmonary Disease (COPD) Obstructive Sleep Apnea Syndrome (OSAS) Men or women between 18 and 80 years old Patient with planned coronary artery bypass graft surgery Patient with planned peripheral vascular surgery Patient with aortic surgery  Patient with aortic or mitral valvular replacement Patient with emergency peripheral valvular surgery Patient with emergency coronary artery bypass graft surgery Patient with evolutive malignancy disease Pregnant or lactating women Patient with inadvisable bronchodilator (used for functional respiratory) exploration
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 50.0-80.0,  COPD (1) age between 50 and 80 years; (2) a post-bronchodilator forced expiratory volume in one second (FEV1) < 80% of the predicted value and a FEV1/ forced vital capacity (CVF) ratio < 0,7; (3) stable respiratory/clinical condition without changes in medication and symptoms (dyspnea, volume or color of sputum) for at least 4 weeks before admission to the study; and (4) receiving regular treatment with inhaled bronchodilators and steroids  (1) presence of other pulmonary, cardiovascular or musculoskeletal diseases; (2) previously participation in any exercise-training program in the last 2 years before participating in this study; and (3) current smokers
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 35.0-85.0,  Chronic Obstructive Pulmonary Disease chronic obstructive pulmonary disease GOLD stage III or IV acute exacerbation of the disease  contraindications for transcutaneous electrical muscle stimulation
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Floppy Iris Syndrome Male years or older Scheduled for Cataract Surgery Current or Past use of Tamsulosin (flomax) Blue colored iris For controls, no history of Flomax  Females Diabetes Glaucoma Use of medicated eye drops Trauma or prior surgery to the eye Black or brown iris